Navigation Links
NewCardio to Introduce Technology at Heart Rhythm Society Conference
Date:5/14/2009

Platform Technology, QTinno(TM) and Visual3Dx(TM) to be introduced at prestigious conference

Information located at booth 468

SANTA CLARA, Calif., May 14 /PRNewswire-FirstCall/ -- NewCardio, Inc., (OTC Bulletin Board: NWCI) a cardiac diagnostic and services company, today announced that the Company will introduce the NewCardio platform, QTinno(TM) and Visual3Dx(TM) at Heart Rhythm 2009, today through May 16, 2009. The Company will be located at booth number 468 at the Boston Convention and Exhibition Center (BCEC), at 415 Summer Street, Boston, MA.

The Company believes that its QTinno(TM), software-based, analytical technology is the industry's first solution for the reliable automated analysis of ECGs used to determine cardiac toxicity during drug development. Visual3Dx(TM) will generate 3D information from the heart using standard 12-lead ECG data. It is expected to provide clinicians additional information on the extent and location of damage to the heart caused by a myocardial infarction to improve the speed and accuracy of diagnosis.

HRS is the international leader in science, education and advocacy for cardiac arrhythmia professionals and patients, and the primary information resource on heart rhythm disorders. Its mission is to improve the care of patients by promoting research, education and optimal health care policies and standards. The Annual Scientific Sessions attract more than 9,000 professionals representing the allied specialties of cardiac pacing and cardiac electrophysiology.

Mr. Vincent Renz, NewCardio's president and chief operating officer commented, "Our 3D technology brings a new dimension to the way the medical world looks at ECGs, the most widely used diagnostic test in cardiology. We are excited and proud to introduce our innovative applications, based on our platform technology, at this important and well-respected conference."

About NewCardio, Inc.

NewCardio is a cardiac diagnostic and services company focused on the development of a proprietary platform technology to provide higher accuracy to, and increase the value of, the standard 12-lead electrocardiogram (ECG). NewCardio's development-stage software and hardware products and services are intended to improve the diagnosis and monitoring of cardiovascular disease (CVD), as well as cardiac safety assessment of drugs under development. NewCardio's three-dimensional ECG platform is designed to reduce the time and expense involved in assessing cardiac status while increasing the ability to diagnose clinically significant conditions which were previously difficult to detect. For more information, visit www.newcardio.com.

Forward-Looking Statements

This press release contains forward-looking statements. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any other statements relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates and projections about our business based on currently available information and assumptions made by management. Although we believe that the assumptions on which the forward-looking statements contained herein are based are reasonable, any of those assumptions could prove to be inaccurate given the inherent uncertainties as to the occurrence or nonoccurrence of future events. These statements are not guarantees of future performance and involve risks and uncertainties that are difficult to predict. Therefore, actual outcomes and results may, and are likely to, differ materially from what is expressed or forecasted in the forward-looking statements due to numerous factors, including the potential risks and uncertainties set forth in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2008 and relate to our business plan, our business strategy, development of our proprietary technology platform and our products, timing of such development, timing and results of clinical trials, level and timing of FDA regulatory clearance or review, market acceptance of our products, protection of our intellectual property, implementation of our strategic, operating and people initiatives, benefits to be derived from personnel and directors, ability to commercialize our products, our assumptions regarding cash flow from operations and cash on-hand, the amount and timing of operating costs and capital expenditures relating to the expansion of our business, operations and infrastructure, implementation of marketing programs, our key agreements and strategic alliances, our ability to obtain additional capital as, and when, needed, and on acceptable terms and general economic conditions specific to our industry, any of which could impact sales, costs and expenses and/or planned strategies and timing. We assume no obligation to, and do not currently intend to, update these forward-looking statements.

To join our email distribution please click this link: http://www.b2i.us/irpass.asp?BzID=1645&to=ea&s=0

    Investor Contact:
    Hayden IR
    Jeff Stanlis
    Partner and Vice President of Communications
    (602) 476-1821
    jeff@haydenir.com


'/>"/>
SOURCE NewCardio, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. NewCardio Leadership to Make Two Presentations at Drug Information Association Drug Safety Conference
2. NewCardio Elects Michael E. Hanson to Board of Directors
3. UPDATE: NewCardio Leadership to Present Clinical Data of Fully Automated QTinno(TM) Study at American College of Cardiology Annual Meeting
4. NewCardio Leadership to Present Clinical Data of Fully Automated QTinno(TM) Study at American College of Cardiology Annual Meeting
5. NewCardio to Present at OneMedForum 2009: Disrupters and Drivers on January 13 in San Francisco
6. NewCardio Restructures 2007 Financing, Receives $2.8 Million Additional Cash and Improves Capital Structure
7. NewCardio Announces New Client Services Team
8. LightLab Imaging Introduces Worlds Highest Resolution OCT System for Intracoronary Imaging at EuroPCR 2009
9. Blue Cross/Blue Shield Of Massachusetts Introduces Controversial Criteria For Vein Treatment Reimbursement
10. Park Meadows Cosmetic Surgery, a Pioneer in DIEP Flap Breast Reconstruction Surgery in Colorado, Introduces New, Informative Website
11. Ultimate Ice Wraps Introduces Best of Class Cold Therapy Product to the Worldwide Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... Cary, NC (PRWEB) , ... May 04, 2016 , ... ... database in the world. The Duke Clinical Research Institute (DCRI) and analytics leader SAS ... of cardiovascular patient data collected by the Duke University Health System. , The ...
(Date:5/4/2016)... ... May 04, 2016 , ... All-Star Insurance of Northeast ... the people of their local community. The agency pledges to select a new ... hope is to bring awareness to important local causes with fundraising and other ...
(Date:5/4/2016)... (PRWEB) , ... May 04, 2016 , ... May kicked ... in people across the United States. Dermatologist Dr. Ellen Turner is encouraging her patients, ... experts’ advice and focus on skin safety and health now and in the future. ...
(Date:5/4/2016)... ... 04, 2016 , ... Dr. Elyson and Dr. Assili, dentist in Northridge ... Wisdom tooth removal, a common dental procedure, is performed for many adolescents and young ... resulting in risks of complications. By providing wisdom tooth removal surgery at their office, ...
(Date:5/4/2016)... ... May 04, 2016 , ... Nordic Naturals announces another ... metabolic health. This synergistic combination of omega-3 fatty acids and potent antioxidants contains ... of reduced glutathione and 200 mg of N-Acetylcysteine (NAC). , Each nutrient ...
Breaking Medicine News(10 mins):
(Date:5/3/2016)... LAKE OSWEGO, Ore. , May 3, 2016 ... and endovascular medical technology, today announced Food and ... a cardiac resynchronization defibrillator that provides heart failure ... (MRI) scans. Iperia devices also have remote monitoring ... (CLS) that adapts the heart rate in response ...
(Date:5/3/2016)... YORK , May 3, 2016 ... (MRI) Market Size, Share, Development, Growth and Demand Forecast ... Open), by Field Strength (High Field, Very High Field, ... Application (Brain, Head and Neck, Spine, Musculoskeletal, Vascular, Breast, ... the global magnetic resonance imaging (MRI) market was valued ...
(Date:5/3/2016)... 2016 Norgine B.V. ... einen entscheidenden Meilenstein durch diese Veröffentlichung zur  ... Handeln, um Patientenresultate  bei Verdauungs- und Lebererkrankungen ... im Verständnis der Hepatischen Enzephalopathie bei und ... Hepatische Enzephalopathie in der Öffentlichkeit zu schaffen ...
Breaking Medicine Technology: